Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: BioTime, Inc.

Market Cap 314M 276M 254M 238M 446M 29.76B 453M 3.05B 1.18B 14.6B 1.18B 1.15B 50.74B P/E 2026 *
-18x
P/E 2027 * -13.8x
Enterprise Value 314M 276M 254M 238M 446M 29.76B 453M 3.05B 1.18B 14.6B 1.18B 1.15B 50.74B EV / Sales 2026 *
17.5x
EV / Sales 2027 * 17.4x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
+7.37%-11.55% - - 314M
+2.96%+4.21%-8.16%-2.76% 43.24B
+2.55%+8.99%+326.22%+568.73% 35.25B
+1.23%+4.40%+7.00%+53.68% 30.22B
+2.44%-4.13%+10.70%-19.76% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+2.79%+2.32% - - 14.16B
+2.33%+0.73%+50.64%+108.13% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+1.43%+5.57%+104.83%+94.65% 12.54B
Average +2.07%-0.78%+63.09%+103.98% 23.69B
Weighted average by Cap. +1.49%-0.72%+69.57%+121.18%

Financials

2026 *2027 *
Net sales 17.94M 15.76M 14.52M 13.59M 25.47M 1.7B 25.9M 174M 67.49M 834M 67.34M 65.89M 2.9B 18.09M 15.89M 14.65M 13.71M 25.69M 1.71B 26.12M 176M 68.07M 841M 67.92M 66.46M 2.92B
Net income -23.79M -20.9M -19.26M -18.03M -33.77M -2.25B -34.34M -231M -89.5M -1.11B -89.3M -87.38M -3.84B -31.66M -27.81M -25.63M -23.99M -44.95M -3B -45.71M -308M -119M -1.47B -119M -116M -5.11B
Net Debt - -
Logo BioTime, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!